Mads Kreilgaard

Principal Specialist
Novo Nordisk A/S
2860 Soeborg, Hovedstaden, Denmark

Presentation(s):

• PB0156 - Higher Thrombin Generation Is Predicted When Switching Directly From Emicizumab to MIM8 in Patients With Hemophilia A

  Sunday, June 25, 2023
  18:30 – 19:30 ET

• PB1315 - Weight-band dosing with Mim8: using modelling to support a streamlined approach to haemophilia A treatment

  Tuesday, June 27, 2023
  18:30 – 19:30 ET